Kornimate/medical-research-clean huggingface dataset:
role of multislice ct in diagnosis of inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: aim of the work: to evaluate the role of ct in diagnosis of ibd

inflammatory bowel disease (ibd): is a chronic idiopathic disease affecting the gastrointestinal (gi) tract that is comprised of two separate, but related intestinal disorders; crohn s disease (cd) and ulcerative colitis (uc), ibd is thought to result from an exaggerated and inappropriate immune response to gut luminal microbes in genetically, susceptible individuals who are exposed to environmental risk factors. ibd is most common in north america and western and northern europe, where incidence rates for uc and cd range from 2.2-24.3 per 100000 person years, it is estimated that more than 1.4 million americans and as many as 2.5-3 million, europeans have ibd. while uc and cd share some features, the diseases are distinct. perhaps the most important differences are that while the chronic inflammation seen in uc is limited to the large intestine and affects only the intestinal mucosa, the inflammation in cd can occur at any location(s) along the gi tract and is often transmural, predisposing patients with cd to the development of penetrating (fistulizing) and fibro stenotic (stricturing) phenotypes that are not typically seen in uc. in some cases, uc and cd are not distinguishable and a diagnosis of ibd unclassified (ibd-u) is made although clinical features of ibd-u tend to mirror those of uc clinical manifestations of uc include diarrhea, with or without blood, abdominal pain, tenesmus, and fecal urgency, while the manifestations of cd are more variable depending on the extent and location of the gi inflammation. cd with predominantly colonic involvement often presents in similar fashion to uc whereas in small bowel cd, diarrhea and rectal bleeding are seen less frequently and symptoms, fever, fatigue and weight loss are common.

Eligibility criteria:
inclusion criteria: * patient in the age group between 15\&40 and another age group between 50\&80 with inflammatory bowel disease. exclusion criteria: * patients with any general contraindication to radiation of ct especially pregnant women. * patients with any general contraindication to contrast, impaired renal function \& hypersensitivity. * patients of the age group below 15 years old.
astaxanthin effects on osteoarthritis associated pain and inflammatory indicators

Conditions: Osteoarthritis, Knee

Summary: this study is intended to assess the effects of astaxanthin use on pain, physical function, and inflammation as reflected by patient-reported outcomes measurement information system (promis) scores and levels of inflammatory biomarkers in subjects taking astaxanthin. if improvements in pain, function, and/or markers of inflammation could be demonstrated with the use of astaxanthin, this may suggest the potential for astaxanthin to be used in management of knee osteoarthritis (and possibly other forms of osteoarthritis) with less evident toxicity than seen with the presently available standard therapies (e.g. nsaids, opioids).


Eligibility criteria:
inclusion criteria: * age 18 years or older * symptoms of knee pain * radiographic evidence of mild to moderate arthritis * able to provide written consent on their own behalf exclusion criteria: * pregnancy * current tobacco use * current substance abuse (alcohol or drug) * presence of significant cardiovascular, pulmonary, hepatic, or renal disease * prior history of knee trauma or surgery * gout or pseudogout * significant depression or anxiety scores on phq-9 and gad-7, or pre-existing diagnosis of a significant mental health disorder * presence of other chronic pain syndromes such as chronic low back or neck pain, fibromyalgia, or complex regional pain syndrome * presence of systemic inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease * symptomatic involvement of multiple other joints with osteoarthritis * known allergy to fish or astaxanthin * bmi greater than 35 * participation in another clinical trial
calhoun vision light adjustable lens (lal) in subjects with pre-existing corneal astigmatism

Conditions: Cataract

Summary: the purpose is to evaluate the calhoun vision light adjustable lens (lal) and light delivery device (ldd) for reducing astigmatism and improving uncorrected vision after implantation.


Eligibility criteria:
inclusion criteria: * undergoing cataract surgery and be willing to have lal or commercially available iol implanted * pre-operative regular corneal astigmatism of \>= 0.75 diopters and \<= 2.0 diopters * best spectacle corrected visual acuity reduced to 20/40 or worse with or without glare * projected best spectacle corrected visual acuity of 20/20 or better * clear intraocular media other than cataract * potentially good vision in fellow eye * fully dilated pupil of \>= 7.0 mm exclusion criteria: * zonular laxity or dehiscence * pseudoexfoliation * age related macular degeneration * retinal degenerative disorder * diabetes with any evidence of retinopathy * glaucomatous optic neuropathy, uveitis, significant anterior segment pathology, keratoconus * corneal dystrophy, previous corneal or intraocular surgery * complications during cataract surgery * serious co-morbid conditions * systemic medications that my increase uv sensitivity * irregular astigmatism
the mechanism and prognosis of pulmonary circulation dysfunction

Conditions: VTE

Summary: venous thromboembolism (vte) is a condition which influenced by both environmental and genetic factors. this study is going to explore new significant single nucleotide polymorphisms (snps) associated with vte by genome-wide association studies (gwas) and bioinformatics analysis. transcriptomics and cytokine antibody array are also used to find new biomarkers of vte's early diagnosis, severity and prognosis.


Eligibility criteria:
inclusion criteria: * chinese han population older than 14 years old * acute vte patients diagnosed in 1 month * with informed consent exclusion criteria: * patients with psychosis * patients with contraindications for computed tomographic pulmonary angiography (ctpa) * chronic vte * recurrence of chronic vte

Keywords: vte snp biomarkers
clinical study investigating safety and performance of a new urinary intermittent catheter in healthy volunteers

Conditions: Incontinence, Urinary

Summary: the aim of the study is to test the performance and safety of a newly developed intermittent catheter in healthy volunteers.


Eligibility criteria:
inclusion criteria: 1. have given written informed consent and signed letter of authority 2. be at least 18 years of age and have full legal capacity 3. be a male 4. willing to refrain from using analgetics up to 24 hours prior to catheterization visits 5. have a negative urine multistix - erythrocytes (microscopic haematuria) 6. have a negative urine multistix: * leukocytes * nitrite or if positive, subsequent negative for bacterial growth in urine culture exclusion criteria: 1. abnormalities, diseases or surgical procedures performed in the lower urinary tract 2. symptoms of urinary tract infections (at least one of the following: frequent urination, stinging or pain at urination) 3. participating in other clinical investigations related to urinary tracts system during this investigation (inclusion to termination) or have previously participated in this investigation 4. known hypersensitivity toward any of the test products -
a cognitive intervention to manage 'brain fog' in menopause transition: feasibility study

Conditions: Menopause

Summary: cognitive complaints at menopause transition (mt), often described as 'brain fog'; can include difficulty recalling words and numbers, misplacing items, trouble concentrating and forgetfulness. whilst these difficulties resolve for most people, several years of reduced cognitive functioning can be highly damaging and result in problems including leaving work, depression and relationship breakdown. study aims: this project aims 1) to develop and finalise a cognitive intervention for the menopause, 2) to evaluate the feasibility, acceptability and preliminary effects of the intervention. 3) to evaluate the interventions preliminary effects on subjective and objective cognition relevance: traditionally menopause hormone therapy (mht) is offered to women with cognitive complaints due to its beneficial effect. however, many women are unable to take it due to medical reasons or choose not to. if this intervention is concluded as feasible and acceptable it may then be appropriate to conduct a full rct of this intervention. it could reduce excess disability, potentially enabling people to remain at work and function better in daily life. costs to the nhs might be reduced through decreased service and medication use.


Eligibility criteria:
inclusion criteria: * people with ovaries (women, trans-men and non-binary people) aged 40-60 * late-reproductive, early-late perimenopause or early post-menopause stages according to the stages of reproductive aging workshop (straw+10; harlow et al., 2012) * stable dose of hormonal (oestrogen, progesterone, testosterone) or antidepressant (ssri, ssni) medication for 6 months or more * self-reported cognitive difficulties impacting on quality of life * ability to communicate in english exclusion criteria: * diagnosis of dementia * new regimen (under 6 months) of medication likely to impact on cognition (i.e. hormonal or anti-depressant)
effect of abdominal wall injections on abdominal pain

Conditions: Anterior Cutaneous Nerve Entrapment Syndrome

Summary: this is a prospective cohort study of outpatient adults with chronic abdominal wall pain receiving abdominal wall injections, as part of their usual care, with lidocaine. subjects will be recruited at the outpatient gastroenterology clinic at ohsu.

this is a prospective cohort study of outpatient adults with chronic abdominal wall pain who receive abdominal wall injections with lidocaine at an academic medical center. thirty patients will be enrolled. a baseline assessment will include a medical history review and survey administration (pain catastrophizing scale, psychological inflexibility in pain scale, patient-reported outcomes measurement information system-29, recurrent abdominal pain intensity and disability scale). subjects will undergo quantitative sensory testing to measure their pain tolerance and thresholds. the primary outcome to be measured is the change in abdominal wall pain at 1 week, 4 weeks and 12 weeks following the abdominal wall injection, with improvement defined as a 50% reduction in baseline pain score measured using an 11-point numeric scale. data analysis will consist of basic summary statistics to describe the mean, median, and standard deviation for demographic variables and clinical measures. a one-sample t-test or wilcoxon test will be used to compare differences in continuous values between time points. chi-square tests will be used to compare differences in categorical variables. an alpha of 0.05 will be used for all statistical tests. univariate and multivariate logistic regression will be used to assess for factors associated with pain reduction.

Eligibility criteria:
inclusion criteria: * localized abdominal wall pain * average daily pain (7-day recall) ≥ 3 on a scale of 0-10 * suspected abdominal wall etiology for abdominal pain * positive carnett's sign or pain near an incisional site * 18 years of age or older exclusion criteria: * suspected visceral etiology for the abdominal pain * severe allergy to lidocaine * unwillingness or inability to provide informed consent * low probability of follow-up * abdominal wall hernia noted at the point of pain * history of trigger point injections for abdominal pain * bleeding disorder * pregnancy, incarceration or decisionally impaired
process and outcomes of horticultural therapy for people with disabilities

Conditions: Mental Disorders, Severe; Intellectual Disability

Summary: horticultural therapy (ht) "is the engagement of a client in horticulture activities facilitated by a trained therapist to achieve specific and documented treatment goals" (american horticultural therapy association, 2012). people's interactions with plants, through goal-orientated horticultural activities in the form of active gardening, as well as the passive appreciation of nature, could be therapeutic to people with mental or intellectual disabilities in many ways (eling, 2006; parkinson, lowe, \& vecsey, 2011). this study aims to conduct evaluation studies of ht group programmes for care home residents with severe mental illness.

this is a randomized, single-blind, controlled study in which the outcomes of the horticultural therapy program is compared with a comparison group. outcome measures were compared at pre-intervention and post-intervention.

Eligibility criteria:
inclusion criteria: * diagnosis of severe mental disorder, e.g. schizophrenia, schizoaffective disorder, bipolar disorder. * age 18 - 65. * care home resident exclusion criteria: * organic brain disorder * difficulties in communication for joining horticultural activity.

Keywords: horticultural therapy severe mental illness care home residents
multiple ascending dose trial of msb0010841 (anti-il17a/f nanobody) in psoriasis subjects

Conditions: Psoriasis

Summary: this is a multicenter, phase 1, randomized, double-blind, placebo-controlled trial in subjects with moderate to severe psoriasis to assess the safety, tolerability, immunogenicity, pharmacokinetics (pk), pharmacodynamics (pd) and efficacy of multiple subcutaneous ascending doses of msb0010841 (anti-interleukin-17a/f \[anti-il-17a/f\] nanobody).


Eligibility criteria:
inclusion criteria: * chronic plaque psoriasis for at least 6 months before screening * greater than or equal to (\>=) 10% of bsa with plaques * psoriasis area and severity index (pasi) \>=12 * static physician's global assessment (spga) \>=3 (where scores range from 0 \[clear of disease\] to 5 \[severe disease\]) at the screening and baseline visits * other protocol defined inclusion criteria could apply exclusion criteria: * any condition, including protocol-specified laboratory findings and findings in the medical history or in the pre-trial assessments which in the investigator's opinion constitutes a risk or a contraindication for the subject's participation in the trial or that could interfere with the trial objectives, conduct or evaluation * currently having a form of non-plaque psoriasis as specified in the protocol * drug induced psoriasis * biological treatments as specified in the protocol, within 3 months prior to day 1 * systemic immunosuppressants or phototherapy as specified in the protocol, within 1 month prior to day 1 * use of anti-coagulant medications and/or antiplatelet medications as defined in the protocol * use of aspirin as defined in the protocol * topical corticosteroid treatments other than low-strength or lower-mid strength corticosteroids on the face, scalp, axillae, and/or groin within 1 month prior to day 1 * any previous treatment with an agent targeting interleukin (il)-17, il-12 and/or il-23 as specified in the protocol * other protocol defined exclusion criteria could apply

Keywords: psoriasis msb0010841 anti-il17a/f nanobody m1095
a phase i trial of donor- derived 19-28z car t cells following allogeneic transplant for the treatment of cd19 malignancies

Conditions: Leukemia; Lymphoma; Lymphoma, B-Cell

Summary: the purposed of this study is to determine whether an infusion with specialized 'modified t cells' (or cd19 chimeric antigen t cells, also called cd19 car t cells) that target the b cell marker will reduce the risk of relapse after transplant.


Eligibility criteria:
inclusion criteria: the following criteria must be met prior to the allogenic transplantation: 1. all in second remission or greater (≥ cr2) * please refer to section 3.0 for more discussion of all in cr1 versus cr2 2. cll 1. high risk in any remission status as defined by 17p deletion or richter's transformation, or 2. all other patients eligible after at least 2 lines of standard or investigational chemotherapy 3. b-nhl 1. refractory or stable disease to last line of therapy per icml 2014. patients should have at least 2 lines of prior therapy. 2. relapsed disease in patients who are not candidates for autologous transplant 4. patient's age is ≥ 18 and ≤ 60. 5. kps ≥ 70% 6. patients must have cd19 expression (by any detection method) demonstrated on their malignant cells at the time of enrollment on the protocol. 7. patients relapsed after prior cd19 car t cell or blinatumomab are eligible for enrollment as long as cd19 expression is still prese on the malignant cells. 8. patients who have a matched related donor willing to donate hsc for allograft and pbmc for car t cell generation 9. patients must have adequate organ function measured by: 1. cardiac: asymptomatic or if symptomatic then lvef at rest must be \> 50% 2. hepatic: \< 3x uln alt and \< 1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia. 3. renal: serum creatinine \ 60 ml/min (measured or calculated/estimated) 4. pulmonary: asymptomatic or if symptomatic, dlco \> 50% of predicted (corrected for hemoglobin) 5. negative serum pregnancy test for women of child-bearing potential is required exclusion criteria: 1. active and uncontrolled infection at time of transplantation. please note that patients being actively treated for a viral reactivation may be enrolled on the protocol at the discretion of the investigators. 2. patients who have undergone a prior allogeneic or autologous stem cell transplant within the previous six months. 3. pregnant or breast feeding 4. hiv infection 5. progressive disease at time of transplant 6. patients with known autoimmune disease. 7. patients with active or clinically significant neurological disorders, such as seizure disorders.

Keywords: leukemia lymphoma lymphoma, b-cell chimeric antigen receptor (car) t cells cart cells high-risk b-cell malignancies 17-331 memorial sloan kettering cancer center
effects of dark vs. white chocolate on the postprandial increase in portal pressure in cirrhosis

Conditions: Cirrhosis; Portal Hypertension

Summary: this study was aimed at testing the hypothesis that supplementing a meal with dark chocolate, which holds potent antioxidant properties, might attenuate the postprandial increase in the hepatic venous pressure gradient (hvpg, clinical equivalent of portal pressure) in patients with cirrhosis

previous studies showed that the intrahepatic circulation in cirrhosis is not able to adapt to sudden increases in blood flow, such as that occurring after a meal, due to endothelial dysfunction. this leads to a brisk increase in portal pressure (estimated by the hvpg). this method is therefore useful to assess the efficacy of compounds potentially ameliorating intrahepatic endothelial dysfunction. dark chocolate, which contains a high proportion of cocoa flavonoids such as cathechin and epicatechin- powerful antioxidants, increases no availability in the systemic circulation and improves systemic endothelial function. we hypothesised that the antioxidant properties of dark chocolate could be beneficial in patients with cirrhosis, since they might improve intrahepatic endothelial dysfunction. consequently, the aim of this study was to evaluate whether a dark chocolate-containing test meal may attenuate the post-prandial increase in hvpg in patients with cirrhosis and portal hypertension. hvpg was measured at baseline and 30 minutes after the administration of a test meal supplemented by either dark or white chocolate. portal vein blood flow and hepatic artery blood flow were measured by doppler ultrasound. catechins and nox were determined for both timepoints.

Eligibility criteria:
inclusion criteria: 1. age over 18 years 2. diagnosis of cirrhosis (proven by biopsy or clinical, laboratory and imaging procedures) 3. presence of esophageal varices of any grade 4. hvpg ≥ 10 mmhg during the hemodynamic study exclusion criteria: 1. food allergy to chocolate 2. ongoing treatment with ascorbic acid and/or other antioxidants 3. diffuse or multinodular hepatocellular carcinoma 4. pregnancy 5. advanced hepatic failure (defined as prothrombin ratio \ 5 mg/dl) 6. renal failure (defined by a serum creatinine level \> 1.5 mg/dl) 7. portal vein thrombosis 8. cardiac or respiratory failure 9. previous surgical or transjugular intrahepatic portosystemic shunt

Keywords: dark chocolate catechins intrahepatic endothelial dysfunction cirrhosis portal hypertension
assessment of safety and efficacy of thiscart19a in adult patients with b-nhl after failure of autologous chimeric antigen receptor t- cell(car-t) therapy

Conditions: Non-Hodgkin's Lymphoma

Summary: this is a phase i, single center study to assess the efficacy and safety of thiscart19a in adult with non-hodgkins lymphoma in china.


Eligibility criteria:
inclusion criteria: * cellular or histopathological diagnosis of b-cell non-hodgkin's lymphoma (b-nhl) includes: diffuse large b-cell lymphoma (dlbcl), follicular lymphoma to dlbcl (tfl), follicular lymphatic (fl), mantle cell lymphoma (mcl), primary mediastinal large b-cell lymphoma (pmbcl), etc. * failing to autologous car-t therapy. * at least one available lesion to be assessed. * good organ function during screening. * should be confirmed cluster of differentiation(cd)19 positive by biopsy for the patient who received target cd19 therapy before. exclusion criteria: * allergic to preconditioning measures. * patients with other malignancies other than b-cell malignancies within 5 years prior to screening. patients with cured skin squamous carcinoma, basal carcinoma, non-primary invasive bladder cancer, localized low-risk prostate cancer, in situ cervical/breast cancer can be recruited. * uncontrollable bacterial, fungal and viral infection during screening. * patients had pulmonary embolism within 3 months prior to enrollment. * had intolerant severe cardiovascular and cerebrovascular diseases and hereditary diseases prior to enrollment. * imaging confirmed the presence of central nervous system involvement (both primary and secondary) and obvious symptoms at the time of screening. * active hepatitis b virus (hbv) or hepatitis c virus (hcv) or human immunodeficiency virus (hiv) or syphilis infection. hbv-dna \< 2000 iu/ml can be enrolled, but should admitted to use anti-virus drugs such as entecavir, tenofovir, etc, and supervisory the relative indication during the treatment. * had big lesion(single lesion diameter ≥10 cm). * bone marrow involvement≥5%. * receive allogeneic hematopoietic stem cell transplantation less than 100 days. * combined systemic steroid use (e.g., prednisone ≥20mg) within 3 days prior to screening. or systemic diseases that require long-term use of immunization inhibitor. * vaccinated with influenza vaccine within 2 weeks prior to lymphodepleting chemotherapy (severe acute respiratory syndrome-corona virus disease 19 can be included, inactivated, live/non-live adjuvant vaccinations allowed to be included) . * patients who are receiving graft versus host disease hepatitis(gvhd) treatment; patients without gvhd and who had stopped immunosuppressive drugs for at least 1 month were eligible for inclusion. * women who are in pregnant or lactating, and female subjects or partners who plan to be pregnant within 1 year after cell infusion. male subjects who plan pregnancy within 1 year after infusion.